Multistate Antitrust Action

Attorney General Pam Bondi and 39 other state attorneys general today filed an amended complaint in federal court, against several generic drug makers for allegedly fixing prices and allocating customers in the generic drug market. According to the amended complaint, the drug companies illegally conspired to artificially inflate and manipulate prices and reduce competition in the United States for two generic drugs. These drugs are doxycycline hyclate delayed release, an antibiotic, and glyburide, an oral diabetes medication. 
The amended complaint filed today increases from 19 to 39 the number of plaintiff states joining Florida in a multistate action originally filed in federal district court in Connecticut in December 2016. The complaint also adds certain state and consumer protection claims, including violations of Florida’s Antitrust and Deceptive and Unfair Trade Practices Acts.
To view the public version of the amended complaint, click here.
The drug makers named in the complaint include: Auribindo Pharma USA, Inc., Citron Pharma, LLC, Heritage Pharmaceuticals, Inc., Mayne Pharma (USA), Inc., Mylan Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.
For more information on the action filed last year, click here.